The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I study of TT-00420, a multiple kinase inhibitor, as a single agent in advanced solid tumors.
 
Sarina Anne Anne Piha-Paul
Consulting or Advisory Role - Merck
Research Funding - Abbvie (Inst); ABM (Inst); Acepodia (Inst); Alkermes (Inst); Aminex (Inst); Amphivena Therapetics, Inc. (Inst); Biomarin (Inst); Boehringer Ingelheim (Inst); Bristol Myers Squib (Inst); Cerulean Pharma (Inst); Chugai Pharma (Inst); Curis (Inst); Daichi Sanko (Inst); ENB Therapeutics (Inst); Five Prime Therapeutics (Inst); Gene Quantum (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Helix BioPharma (Inst); Incyte (Inst); Jacobio (Inst); Lilly (Inst); MedImmune (Inst); Medivation (Inst); Merck Sharp and Dohme Corp. (Inst); NIH/NCI (Inst); Novartis (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Principa Biopharma (Inst); Puma Biotechnology (Inst); RAPT Therapeutics (Inst); Seagen (Inst); Silverback Therapeutics (Inst); Taiho Oncology (Inst); Tesaro (Inst); TransThera Biosciences (Inst); XuanZhu (Inst)
 
Binghe Xu
Speakers' Bureau - AstraZeneca; Eisai; Pfizer; Roche
Research Funding - Jiangsu Hengrui Medicine (Inst)
 
Filip Janku
Stock and Other Ownership Interests - Trovagene
Consulting or Advisory Role - Deciphera; Foundation Medicine; Guardant Health; IDEAYA Biosciences; IFM Therapeutics; Immunomet; Jazz Pharmaceuticals; Novartis; PureTech; Sequenom; Sotio; Synlogic; Trovagene; Valeant/Dendreon
Research Funding - Agios (Inst); Asana Biosciences (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Deciphera (Inst); Fujifilm (Inst); Genentech (Inst); Novartis (Inst); Piqur (Inst); Plexxikon (Inst); Proximagen (Inst); Roche (Inst); Symphogen (Inst)
Other Relationship - Bio-Rad
 
Ecaterina Elena Dumbrava
Consulting or Advisory Role - Bolt Biotherapeutics
 
Siqing Fu
Research Funding - Abbisko (Inst); Anaeropharma (Inst); Arrien Pharmaceuticals (Inst); AstraZeneca (Inst); BeiGene (Inst); BioAtla (Inst); Boehringer Ingelheim (Inst); Hookipa Pharma (Inst); Huya Bioscience International (Inst); IMV (Inst); Innovent Biologics (Inst); Lilly (Inst); Lyvgen Biopharma (Inst); MacroGenics (Inst); Medivir (Inst); Millennium (Inst); NCCN (Inst); NCCN (Inst); Nerviano Medical Sciences (Inst); NeuPharma, Inc. (Inst); NIH/NCI (Inst); Novartis (Inst); NovoCure (Inst); OncoMed (Inst); Parexel International, LLC (Inst); Sellas Life Sciences (Inst); Soricimed (Inst); Taiho Oncology (Inst); Tolero Pharmaceuticals (Inst); Turnstone Bio (Inst)
 
Daniel D. Karp
No Relationships to Disclose
 
Funda Meric-Bernstam
Employment - MD Anderson Cancer Center
Honoraria - Mayo Clinic; Rutgers Cancer Institute of New Jersey
Consulting or Advisory Role - Aduro Biotech; Alkermes; Debiopharm Group; eFFECTOR Therapeutics; Genentech; IBM; Immunomedics; Inflection Biosciences; Jackson Laboratory for Genomic Medicine; Kolon Life Sciences; Mersana; Origimed; PACT Pharma; Parexel International; Pfizer; Puma Biotechnology; Roche; Samsung Bioepis; Seagen; Silverback Therapeutics; Spectrum Pharmaceuticals; Tyra Biosciences; Xencor; Zentalis; Zymeworks
Speakers' Bureau - Chugai Pharma
Research Funding - Abbvie (Inst); Aileron Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (I); Calithera Biosciences (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); eFFECTOR Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Guardant Health (Inst); Jounce Therapeutics (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); PUMA Biotechnology (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Beth Israel Deaconess Medical Center; Taiho Pharmaceutical
 
David S. Hong
Stock and Other Ownership Interests - MolecularMatch; OncoResponse; Presagia
Consulting or Advisory Role - Acuta; Adaptimmune; Alphasights; Amgen; Axiom Biotechnologies; Baxter; Bayer; Boxer Capital; COG; EcoR1 Capital; Genentech; Gerson Lehrman Group; GroupH; GroupH; Guidepoint Global; H.C. Wainwright & Co.; HCW Precision; Infinity Pharmaceuticals; Infinity Pharmaceuticals; Janssen; Medscape; Merrimack; Numab; Pfizer; Prime Oncology; Seagen; ST Cube; Takeda; Tavistock Life Sciences; Trieza Therapeutics; WebMD; WebMD
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Aldai Norte (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); BMS (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Erasca, Inc (Inst); Fate Therapeutics (Inst); Genentech (Inst); Genmab (Inst); Ignyta (Inst); Infinity Pharmaceuticals (Inst); Kite, a Gilead company (Inst); Kyowa (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); miRNA Therapeutics (Inst); Molecular Templates (Inst); Mologen (Inst); National Cancer Institute (Inst); Navire (Inst); Novartis (Inst); Numab (Inst); Pfizer (Inst); Seagen (Inst); Takeda (Inst); Turning Point Therapeutics (Inst); Verastem (Inst); VM Pharma (Inst)
Travel, Accommodations, Expenses - AACR; ASCO; Bayer Schering Pharma; Genmab; Loxo; miRNA Therapeutics; Society for Immunotherapy of Cancer
 
Jordi Rodon Ahnert
Consulting or Advisory Role - Ellipses Pharma; Ionctura; Kelun; Lilly; Merck Sharp & Dohme; Molecular Partners; Novartis; NovellusDx; Orion; Peptomyc; Pfizer; Roche/Genentech; SERVIER; Spectrum Pharmaceuticals
Research Funding - Bayer; BioAtla; Blueprint Medicines; CytomX Therapeutics; Genmab; GlaxoSmithKline; Ipsen; Kelun; Novartis; Pfizer; Spectrum Pharmaceuticals; Symphogen; Takeda/Millennium; Tocagen
Travel, Accommodations, Expenses - Cancer Core Europe; Department of Defense; ESMO; Huntsman Cancer Institute; Karolinska Cancer Institute; King Abdullah International Medical Research Center; Louisiana State University; Molecular Partners
Other Relationship - Chinese University of Hong Kong; Elsevier; European Journal of Cancer; GlaxoSmithKline; SOLTI; Vall d'Hebron University Hospital Institute of Oncology
 
Apostolia Maria Tsimberidou
Consulting or Advisory Role - Tempus
Research Funding - Agenus (Inst); Boston Biomedical (Inst); IMMATICS (Inst); Karus Therapeutics (Inst); OBI Pharma (Inst); Parker Institute for Cancer Immunotherapy (Inst); Placon (Inst); Stem Cells, Inc. (Inst); Tempus (Inst)
Travel, Accommodations, Expenses - Japanese Society of Clinical Oncology
 
Milind M. Javle
Consulting or Advisory Role - AstraZeneca; EMD Serono; incyte; Merck; Mundipharma; oncosil; QED Therapeutics
Other Relationship - Bayer; BeiGene; Incyte; Merck; Merck Serono; Novartis; Pieris Pharmaceuticals; QED Therapeutics; Rafael Pharmaceuticals; Seagen
 
Ying Fan
No Relationships to Disclose
 
Peng Peng
Employment - TransThera Biosciences
Leadership - TransThera Biosciences
Stock and Other Ownership Interests - TransThera Biosciences
Patents, Royalties, Other Intellectual Property - TransThera Biosciences (Inst)
 
Wendy J. Levin
Employment - WJ Levin Consulting
Consulting or Advisory Role - WJ Levin Consulting
 
Brenda Ngo
No Relationships to Disclose
 
Hui Wang
No Relationships to Disclose
 
Caixia Sun
Employment - TransThera Biosciences
 
Qinhua Cindy Ru
Stock and Other Ownership Interests - TransThera Biosciences
Consulting or Advisory Role - ABM (Inst); Cellular Biomedicine Group (Inst); Gene Quantum (Inst); Long Sky Industries Limited (Inst); Phanes Therapeutics (Inst)
 
Frank Wu
Employment - TransThera Biosciences
Leadership - TransThera Biosciences
Patents, Royalties, Other Intellectual Property - TransThera Biosciences (Inst)